PDS Biotechnology
PDSB
31 hedge funds and large institutions have $2.83M invested in PDS Biotechnology in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 11 closing their positions.
0.15% less ownership
Funds ownership: 1.56% → 1.41% (-0.15%)
16% less funds holding
Funds holding: 37 → 31 (-6)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
65% less capital invested
Capital invested by funds: $8.01M → $2.83M (-$5.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$200K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$161K |
| 3 |
WAM
Wealthspire Advisors (Maryland)
Potomac,
Maryland
|
+$66.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$52.7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$40K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$820K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$339K |
| 3 |
Goldman Sachs
New York
|
-$88K |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$64K |
| 5 |
Millennium Management
New York
|
-$52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BNP Paribas Financial Markets
Paris,
France
| $103 | – | – | – |
|
|
GTC
27
Ghost Tree Capital
New York
| – | -$820K | -50,000 | Closed |
|
|
28
Goldman Sachs
New York
| – | -$88K | -5,344 | Closed |
|
|
AAMU
29
Amundi Asset Management US
Boston,
Massachusetts
| – | -$64K | -3,920 | Closed |
|
|
30
Millennium Management
New York
| – | -$52K | -3,189 | Closed |
|
|
ARTA
31
A.R.T. Advisors
New York
| – | -$33K | -2,043 | Closed |
|
|
ECM
32
Element Capital Management
New York
| – | -$32K | -1,933 | Closed |
|
33
UBS Group
Zurich,
Switzerland
| – | -$25K | -1,545 | Closed |
|
34
Jane Street
New York
| – | -$17K | -1,024 | Closed |
|
|
BCM
35
BlueCrest Capital Management
St Helier,
Jersey
| – | -$11K | -655 | Closed |
|
36
Morgan Stanley
New York
| – | -$781 | -59 | -51% |
|
PDSB Hedge Fund Activity: Q4 2018 in Review
31 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2018, worth a combined $2.83M — down 65% from $8.01M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PDSB and 5 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $200K. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $820K sold.
- 31 institutional investors held PDS Biotechnology (PDSB) as of Q4 2018, down from 37 in Q3 2018.
- Funds reported $2.83M of PDS Biotechnology stock for Q4 2018, down 65% quarter-over-quarter.
- 5 funds opened new PDS Biotechnology positions in Q4 2018 and 11 closed out, a net change of -6 holders.
- The largest PDS Biotechnology buyer in Q4 2018 was Renaissance Technologies, an estimated $200K added.
- The largest PDS Biotechnology seller in Q4 2018 was Ghost Tree Capital, an estimated $820K sold.
Based on aggregated 13F filings for Q4 2018.